Alport syndrome is often summarized as an inherited kidney disease accompanied by hearing loss and eye abnormalities. That description is correct, but incomplete. In real life, the condition may present as nothing more than persistent microscopic blood in the urine—or it may be mistaken for focal segmental glomerulosclerosis, another glomerular disease, or chronic kidney disease of unknown cause. Its effects can extend beyond the kidneys, and its severity can differ markedly even within the same family.

 

 

By Majd Isreb, MD, FACP, FASN, IFMC

A Biopsy Pattern Is Not Always the Final Diagnosis

A recently published case report provides a useful example. A patient who carried an FSGS diagnosis underwent genetic testing and was ultimately found to have X-linked Alport syndrome. The FSGS was not the underlying disease; it was a secondary pattern of injury caused by the inherited collagen disorder.

This distinction matters because focal segmental glomerulosclerosis describes a pattern of scarring seen under the microscope, not a single disease with one cause. The 2024 ERKNet/ERA/ESPN guideline specifically recommends including COL4A3, COL4A4, and COL4A5 in genetic panels used to evaluate persistent hematuria, proteinuric kidney disease, FSGS, podocytopathies, and kidney failure of unknown origin.

This is one reason the modern evaluation of kidney disease increasingly combines clinical history, family history, urine findings, kidney pathology, and genetics. A biopsy may show us what happened. Genetics may help explain why.

 

What Is Alport Syndrome?

Alport syndrome is caused by pathogenic variants in COL4A3, COL4A4, or COL4A5. These genes provide instructions for three components of type IV collagen, an essential structural network in several specialized basement membranes.

In the kidney, type IV collagen helps support the glomerular basement membrane, which forms part of the filtration barrier. Related collagen networks are also present in the cochlea of the inner ear and in structures of the eye. This shared biology explains why one genetic disorder can affect filtration, hearing, and vision.

The condition may be inherited in several ways:

• X-linked Alport syndrome, caused by a COL4A5 variant. It is often more severe in males, but females can also develop proteinuria, chronic kidney disease, and kidney failure.
• Autosomal recessive Alport syndrome, caused by pathogenic variants affecting both copies of COL4A3 or COL4A4. It can be severe in males and females.
• Heterozygous COL4A3- or COL4A4-related disease, sometimes called autosomal dominant Alport syndrome. Its expression is highly variable, ranging from isolated hematuria to proteinuria, hypertension, progressive CKD, and—in a smaller subset—kidney failure.

The terminology around heterozygous COL4A3 and COL4A4 variants continues to evolve. What matters clinically is that “thin basement membranes” or a single collagen variant should not automatically be dismissed as harmless. At the same time, not everyone with such a variant will develop advanced disease. Risk assessment must be individualized.

 

 

The Kidney Presentations: From Silent Hematuria to Kidney Failure

Persistent microscopic hematuria

The earliest and most characteristic finding is persistent glomerular hematuria: red blood cells entering the urine through an abnormal filtration barrier. It may be discovered incidentally during childhood, an employment examination, pregnancy, or routine primary-care testing. Because kidney function can remain normal for years, microscopic hematuria may be minimized or attributed to an unrelated cause.

The diagnostic signal becomes stronger when hematuria occurs in several relatives or alongside unexplained kidney failure, proteinuria, sensorineural hearing loss, or characteristic ocular findings.

Albuminuria, proteinuria, and hypertension

As the filtration barrier becomes more vulnerable, albumin begins to appear in the urine. Increasing albuminuria or proteinuria is not merely another laboratory abnormality; it is an important marker of progression risk. Hypertension may follow and adds mechanical stress to an already fragile glomerular basement membrane.

This transition is clinically important because early kidney-protective treatment is most effective before extensive scarring and loss of filtration have occurred.

FSGS and other misleading labels

Later-stage Alport disease can produce podocyte loss and focal segmental glomerular scarring. If the biopsy is interpreted without the broader clinical and genetic context, the patient may be labeled as having primary FSGS. Alport-related variants have also been identified during evaluations for IgA nephropathy, cystic kidney findings, nephrotic-range proteinuria, and kidney failure of uncertain cause.

This does not mean every person with FSGS or hematuria has Alport syndrome. It means that the pathology label should be integrated with the phenotype. Abrupt nephrotic syndrome, rapid kidney decline, or other unexpected features may also signal a superimposed kidney disease rather than Alport syndrome alone.

Women and “carriers”

The word carrier can falsely imply that women with a COL4A5 variant are unaffected. Many have persistent hematuria, and some develop proteinuria, hypertension, progressive CKD, or kidney failure. The current guideline estimates that about 20% of untreated women with X-linked Alport syndrome reach kidney failure by age 60, with substantially lower risk reported when appropriate nephroprotective strategies are used.

Severity is difficult to predict because X-chromosome inactivation varies among cells and tissues. A reassuring family story or mild findings at one point in life do not eliminate the need for lifelong monitoring.

 

Alport Syndrome Beyond the Kidneys

Sensorineural hearing loss

Alport-related hearing loss arises from abnormalities in the inner ear rather than from an obstruction of the ear canal. It is typically bilateral and progressive, often affecting higher frequencies first.

In males with X-linked disease and in people with autosomal recessive disease, it may emerge in later childhood or adolescence, although timing varies. It is less common in females with X-linked disease and in people with a single COL4A3 or COL4A4 variant.

Normal hearing early in life does not exclude Alport syndrome. Periodic audiology is therefore part of risk-stratified surveillance, particularly for groups at higher genetic risk. Early recognition matters for speech, learning, work, communication, and quality of life. Hearing aids can be highly beneficial when needed.

Ocular manifestations

The eye can provide valuable diagnostic clues because type IV collagen contributes to the lens, retina, and cornea. Recognized findings include:

• Anterior lenticonus: forward protrusion of the central lens. When present, it is highly characteristic of Alport syndrome and may cause progressive myopia or visual distortion.
• Dot-and-fleck retinopathy: pale flecks around the macula. It often does not impair vision but can help establish the diagnosis.
• Temporal retinal thinning and characteristic foveal changes detected by optical coherence tomography.
• Recurrent corneal erosion, posterior polymorphous corneal dystrophy, cataracts, and, rarely, macular complications.

Ocular involvement is most common in males with X-linked Alport syndrome and in autosomal recessive disease, and it is uncommon in heterozygous COL4A3/COL4A4-related disease. A complete ophthalmologic examination at diagnosis is reasonable, with subsequent surveillance tailored to genotype, age, symptoms, and specialist guidance.

Rare diffuse leiomyomatosis

A rare contiguous-gene deletion involving COL4A5 and part of the neighboring COL4A6 gene can cause Alport syndrome with diffuse leiomyomatosis. Benign smooth-muscle tumors may involve the esophagus and tracheobronchial tree, producing difficulty swallowing, vomiting after meals, chest or upper abdominal discomfort, cough, recurrent bronchitis, breathing difficulty, or stridor. Genital leiomyomas may also occur in affected females.

This manifestation is uncommon and should not be used to alarm most families with Alport syndrome. It is relevant when the specific deletion is present or when compatible symptoms require investigation.

The Family and Psychosocial Presentation

Alport syndrome affects more than laboratory values. One diagnosis may reveal risk across several generations. Families may face uncertainty about children, pregnancy, kidney donation, future kidney failure, hearing impairment, and the emotional weight of genetic information.

Genetic counseling can clarify inheritance, identify relatives who may benefit from early testing, and support reproductive and living-donor decisions. Children and young adults may also need practical support in school or work when hearing loss, medical appointments, or progressive CKD interfere with daily life.

 

 

When Should Alport Syndrome Be Suspected?

Genetic evaluation deserves consideration when one or more of the following are present:

• Persistent glomerular hematuria, especially when familial
• Hematuria accompanied by albuminuria or proteinuria
• Unexplained CKD or kidney failure in a family
• FSGS or a podocytopathy without a convincing cause
• Characteristic basement-membrane thinning, thickening, splitting, or lamellation on electron microscopy
• Sensorineural hearing loss plus urinary abnormalities
• Anterior lenticonus, characteristic retinal findings, or diffuse leiomyomatosis
• An unexpected response—or lack of response—to treatment prescribed for presumed primary FSGS

Whenever possible, COL4A3, COL4A4, and COL4A5 should be analyzed together. Results must be interpreted in context because variants of uncertain significance do not establish a diagnosis, and some pathogenic variants have incomplete or highly variable expression.

 

 

Treatment: Earlier Kidney Protection Matters

No current lifestyle or medication can replace the abnormal collagen network with a normal one. Treatment instead aims to reduce stress on the filtration barrier, lower albuminuria, control blood pressure, and delay scarring.

Renin-angiotensin system blockade with an ACE inhibitor or angiotensin receptor blocker is the foundation of kidney protection. The current guideline recommends starting and titrating this treatment when microalbuminuria is detected, regardless of the genetic subgroup, with even earlier initiation suggested for higher-risk males with X-linked disease and people with autosomal recessive disease.

The randomized EARLY PRO-TECT Alport trial found ramipril to be safe in children and showed a directionally favorable effect on disease progression, although the randomized comparison was underpowered for a definitive efficacy result.

For adults with albuminuric CKD despite renin-angiotensin system blockade, an SGLT2 inhibitor may also be considered. This recommendation is supported largely by the broader CKD evidence base and emerging Alport-specific observational data; definitive Alport-specific trial evidence remains limited.

Kidney transplantation is an effective treatment for kidney failure caused by Alport syndrome. Potential related donors require careful genetic and kidney evaluation so that an affected relative is not placed at avoidable long-term risk.

 

 

Can Lifestyle Modify the Course of Alport Syndrome?

Lifestyle cannot correct a COL4A3, COL4A4, or COL4A5 variant. It can, however, reduce additional metabolic, vascular, inflammatory, and mechanical stress placed on vulnerable kidneys. The strongest approach combines disease-specific medical treatment with sustainable kidney-supportive habits.

1. Protect blood pressure—and pay attention to sodium

Blood-pressure control is central because higher intraglomerular pressure can accelerate albumin leakage and scarring. A diet built around minimally processed foods and lower in excess sodium can support blood-pressure management and reduce fluid retention. The appropriate sodium target should be individualized, particularly in children, athletes, people with low blood pressure, and those using medications that affect volume or potassium.

2. Avoid high-protein extremes

There is no single “Alport diet,” and protein should not be indiscriminately restricted in growing children or adults at risk for malnutrition. However, very high-protein diets may increase glomerular workload and can aggravate proteinuria. A reasonable pattern emphasizes adequate—not excessive—protein, with greater reliance on plant sources when appropriate and adjustment for CKD stage, nutritional status, potassium, phosphorus, and personal preferences.

3. Favor a diverse, minimally processed dietary pattern

A plant-dominant pattern rich in vegetables, fruits, legumes, whole grains, nuts, seeds, and unsaturated fats can support blood pressure, vascular health, bowel function, and cardiometabolic risk.

This is not a rigid prescription. Advanced CKD, hyperkalemia, kidney stones, gastrointestinal disease, and individual food tolerances may require modification with a renal dietitian.

No supplement, “kidney detox,” or restrictive diet has been proven to repair type IV collagen. Supplements should be reviewed for dose, contamination, drug interactions, and kidney clearance before use.

4. Stay appropriately hydrated without forcing water

Avoiding dehydration is sensible, particularly during illness, heat exposure, exercise, or gastrointestinal fluid loss. But more water is not automatically better, and there is no evidence that forced overhydration repairs the glomerular basement membrane. Fluid intake should be individualized when advanced CKD, edema, heart disease, or impaired urine production is present.

5. Exercise, maintain muscle, and support a healthy weight

Regular cardiovascular and resistance exercise can improve blood pressure, insulin sensitivity, physical function, and long-term cardiovascular health. Maintaining a healthy weight may also reduce hyperfiltration and proteinuria. Exercise plans should be adapted to age, CKD severity, anemia, cardiovascular status, and hearing or visual limitations rather than abandoned because of the diagnosis.

6. Avoid smoking and reduce preventable vascular injury

Smoking adds vascular and oxidative stress to kidneys already at genetic risk. Avoiding tobacco and vaping, moderating alcohol when appropriate, treating diabetes and dyslipidemia, and obtaining adequate sleep all support overall kidney and cardiovascular health. These measures are supportive rather than Alport-specific cures, but their cumulative effect matters over decades.

7. Minimize nephrotoxic exposures

Frequent or unnecessary NSAID use can compound kidney injury. Medications, contrast exposure, herbal products, performance supplements, and over-the-counter preparations should be reviewed with the clinical team. “Natural” does not guarantee kidney safety.

8. Protect hearing and eyes

Avoiding excessive noise exposure is particularly reasonable for people at risk of sensorineural hearing loss. Those with recurrent corneal erosions may need eye protection during activities that expose the cornea to minor trauma. These steps do not prevent genetically driven manifestations, but they may reduce avoidable additional injury.

9. Make monitoring part of the lifestyle plan

One of the most powerful “lifestyle” behaviors is consistent follow-up. Blood pressure, eGFR, urine albumin or protein, hearing, and ocular health should be monitored on a schedule matched to genotype and risk. Medication adherence and early recognition of rising albuminuria can matter more than any single food or supplement.

Pregnancy and Family Planning

People with Alport syndrome or a pathogenic collagen IV variant may benefit from preconception genetic counseling. Pregnancy can increase proteinuria and may unmask or worsen hypertension in susceptible individuals. ACE inhibitors and ARBs are contraindicated during pregnancy and require advance medication planning with nephrology and obstetric teams. The inheritance pattern also determines the probability that a child will inherit the familial variant.

A Practical Whole-Person Checklist

• Know the exact genetic diagnosis and inheritance pattern when testing is informative.
• Monitor blood pressure, kidney function, and urine albumin or protein consistently.
• Use kidney-protective medication early when indicated.
• Arrange risk-appropriate hearing and ophthalmologic evaluation.
• Help at-risk relatives access testing, counseling, and follow-up.
• Choose a sustainable, minimally processed diet without unnecessary blanket restrictions.
• Avoid dehydration, smoking, nephrotoxic medications, and unreviewed supplements.
• Use exercise, sleep, stress management, and social support to protect overall health.
• Plan pregnancy and living donation with specialized genetic and nephrology guidance.

 

 

The Bottom Line on Alport Syndrome

Alport syndrome is not one uniform presentation. It is a spectrum of collagen IV-related disease that may involve the kidneys, hearing, eyes, respiratory or gastrointestinal smooth muscle, and multiple members of a family. Some people develop severe disease early; others remain mildly affected for decades. Even within one family, the trajectory may differ.

The most important shift is to move beyond labels. Persistent hematuria is not always benign. FSGS is not always primary. A woman with an X-linked variant is not “just a carrier.” And lifestyle is neither irrelevant nor a substitute for proven medical therapy.

The best care combines precise genetic diagnosis, early nephroprotection, appropriate surveillance, family-centered counseling, and daily habits that reduce additional stress on the kidneys and cardiovascular system. That is what a truly integrative approach to an inherited kidney disease should look like.